Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Breast 1

Conditions

Breast Neoplasms 55Neoplasm Metastasis 7Triple Negative Breast Neoplasms 6Ovarian Neoplasms 6Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Advanced Breast Cancer 4Prostatic Neoplasms 3Endometrial Neoplasms 3Carcinoma, Ovarian Epithelial 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Hereditary Sensory and Autonomic Neuropathies 2Colorectal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Solid Tumor 1Solid Malignancies 1Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1Pancreatic Neoplasms 1Neoplasms by Site 1Mesothelioma, Malignant 1Mesothelioma 1Lung Neoplasms 1Liposarcoma 1Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer 1

Interventions

pembrolizumab 10Docetaxel 8senaparib 7Injections 7Capecitabine 7Paclitaxel 6Cisplatin 6Irinotecan 5Fluorouracil 5Leucovorin 4Cyclophosphamide 4Bevacizumab 4tislelizumab 3pertuzumab 3fludarabine 3atezolizumab 3Rifampin 3Oxaliplatin 3Itraconazole 3Gemcitabine 3ontuxizumab 2navoximod 2fluzoparib 2durvalumab 2Trastuzumab 2Nivolumab 2Midazolam 2Hydroxychloroquine 2Carboplatin 2130-nm albumin-bound paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Solid Tumor × Fulvestrant × Clear all
NCT04316169 2022-12-23

Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer

Medical College of Wisconsin

Phase 1 Withdrawn
BreastOther solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡